TGFB1 and cancer: However, recent research has revealed that mutations in certain components of the TGF-β signaling pathway exist in many cancers, especially in TGF-β receptor 2 and SMADs13–15, which disrupt signal transduction and the subsequent inhibition of proliferation and apoptosis.